ReviewInvestigative ophthalmology & visual science2016
Stem Cell Sources and Their Potential for the Treatment of Retinal Degenerations.
Review in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04224207 (Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results
Who cites it
24 citing papers in PubMed.
- Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.Stem cell research & therapy · 2020Trial
- A Simple Temperature-Controlled Method for Preserving Viability in Human Pluripotent Stem Cell-Derived Retinal Organoids During Shipment.FASEB bioAdvances · 2026Article
- Review
- Retina-specific laminin-based generation of photoreceptor progenitors from human pluripotent stem cells under xeno-free and chemically defined conditions.Nature protocols · 2025Review
- Evaluation of mesenchymal stem cells as anFrontiers in cell and developmental biology · 2024Review
- Management of Retinitis Pigmentosa Via Wharton's Jelly-Derived Mesenchymal Stem Cells or Combination With Magnovision: 3-Year Prospective Results.Stem cells translational medicine · 2023Article
- Treatment of Inherited Retinal Dystrophies with Somatic Cell Therapy Medicinal Product: A Review.Life (Basel, Switzerland) · 2022Review
- Review
- Extracellular vesicles released by human retinal pigment epithelium mediate increased polarised secretion of drusen proteins in response to AMD stressors.Journal of extracellular vesicles · 2021Article
- Retina stem cells, hopes and obstacles.World journal of stem cells · 2021Review
- Review
- Outer Retinal Cell Replacement: Putting the Pieces Together.Translational vision science & technology · 2021Review
- Pluripotent stem cell therapy for retinal diseases.Annals of translational medicine · 2021Review
- Retinal Stem/Progenitor Cells Derived From Adult Müller Glia for the Treatment of Retinal Degeneration.Frontiers in cell and developmental biology · 2021Review
- Immunologic Rejection of Transplanted Retinal Pigmented Epithelium: Mechanisms and Strategies for Prevention.Frontiers in immunology · 2021Review
- Potential Endogenous Cell Sources for Retinal Regeneration in Vertebrates and Humans: Progenitor Traits and Specialization.Biomedicines · 2020Review
- Paracrine effects of intraocularly implanted cells on degenerating retinas in mice.Stem cell research & therapy · 2020Article
- Retinal stem cell transplantation: Balancing safety and potential.Progress in retinal and eye research · 2020Review
- Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results.Stem cell research & therapy · 2020Article
- Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies.Frontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Stem cells offer unprecedented opportunities for the development of strategies geared toward the treatment of retinal degenerative diseases. A variety of cellular sources have been investigated for various potential clinical applications, including tissue regeneration, disease modeling, and screening for non-cell-based therapeutic agents. As the field transitions from more than a decade of preclinical research to the first phase I/II clinical trials, we provide a concise overview of the stem cell sources most commonly used, weighing their therapeutic potential on the basis of their technical strengths/limitations, their ethical implications, and the extent of the progress achieved to date. This article serves as a framework for further in-depth analyses presented in the following chapters of this Special Issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.